id	等位基因	注释文本
994	*17	The CYP2C1917 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C1917 allele in combination with a normal or increased function allele may have increased metabolism of lansoprazole as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of lansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.
993	*9	The CYP2C199 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C199 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of lansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.
992	*8	The CYP2C198 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C198 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of lansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.
991	*3	The CYP2C193 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C193 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of lansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.
990	*2	The CYP2C192 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C192 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of lansoprazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.
989	*1	The CYP2C191 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C191 allele in combination with another normal function allele may have increased metabolism of lansoprazole as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of lansoprazole as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.

id	证据的ID	总结
1676	1450809629	CYP2C19 1/1 + 1/2 + 1/3 are associated with increased metabolism of lansoprazole in healthy individuals as compared to CYP2C19 2/2 + 2/3 + 3/3.
1675	1450806845	CYP2C19 2/2 + 2/3 are associated with decreased metabolism of lansoprazole in healthy individuals as compared to CYP2C19 1/1 + 1/2 + 1/3.
1674	1183629846	CYP2C19 2/2 is associated with decreased metabolism of lansoprazole in children as compared to CYP2C19 1/2.
1673	1183629838	CYP2C19 1/2 is associated with decreased metabolism of lansoprazole in children as compared to CYP2C19 1/1.
1672	1183623395	CYP2C19 1/1 is not associated with metabolism of lansoprazole or omeprazole in healthy individuals as compared to CYP2C19 1/2.
1671	1183618830	CYP2C19 1/2 + 1/3 is associated with increased metabolism of lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 2/2 + 2/3.
1670	1183618805	CYP2C19 1/1 is associated with increased metabolism of lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 2/2 + 2/3.
1669	1183618564	CYP2C19 1/2 + 1/3 is associated with increased clearance of lansoprazole in healthy individuals as compared to CYP2C19 2/2 + 2/3.
1668	1183618547	CYP2C19 1/1 is associated with increased clearance of lansoprazole in healthy individuals as compared to CYP2C19 2/2 + 2/3.
1667	982047769	CYP2C19 2 + 3 + 8 + 9 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of lansoprazole in children with Asthma as compared to CYP2C19 1/1 (assigned as normal metabolizer phenotype) .
1666	982047065	CYP2C19 2/2 is associated with decreased metabolism of lansoprazole in children as compared to CYP2C19 1/1.
1665	982047056	CYP2C19 17/17 is associated with increased metabolism of lansoprazole in children as compared to CYP2C19 1/1.
1664	1450807240	CYP2C19 poor metabolizers are associated with decreased metabolism of lansoprazole, omeprazole or pantoprazole in healthy individuals as compared to CYP2C19 normal metabolizers.
1663	1450806823	CYP2C19 poor metabolizers are associated with decreased metabolism of lansoprazole in healthy individuals as compared to CYP2C19 normal metabolizers.
1662	PA166104987	Annotation of DPWG Guideline for lansoprazole and CYP2C19
1661	PA166219103	Annotation of CPIC Guideline for lansoprazole, omeprazole, pantoprazole and CYP2C19

id	类型	评论
747	Update	Added DPWG guideline.
746	Update	CA score added as part of scoring system release. LOE assigned following curator review.
745	Update	Change LOE to 1A due to CPIC guideline
744	Update	Updated 'extensive metabolizer' term to 'normal metabolizer' following CPIC Term Standardization Project.
743	Create	Created

最新招商产品更多>>